Britain and America have hammered out a landmark commercial pact that will keep zero levies on UK pharmaceutical shipments being sold in the American market.
The Terms of the Pact
As part of the deal, the UK has committed to increase spending on drugs through the NHS. This commitment secures that import taxes on these key goods will remain at nothing for a timeframe of three years.
This deal comes after previous statements to dramatically increase tariffs on branded drug products, with potential rates discussed up to double the cost.
"This arrangement between the UK strengthens the worldwide climate for new treatments and brings much-needed fairness to transatlantic medicine commerce," a release noted.
Trade Significance
Pharmaceuticals represent one of the Britain's most significant goods shipped to the US, which is easily the largest market for large British pharmaceutical firms.
Statistics show that in the one-year period prior to September, the UK exported drugs worth over eleven billion pounds to the US. This amount made up 17.4% of all goods exports in that timeframe.
"This guarantee secures work, increases funding and sets the stage for the UK to establish itself as a global hub for biotech and pharma," the Business and Trade Secretary stated.
Specific UK Commitments
The agreement involves several specific commitments from the United Kingdom:
- Revised Affordability Limit: The UK will raise the affordability limit at which it considers new treatments to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a aim to raise total health service expenditure on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The percentage drug companies must pay back to the NHS to stay within budget will be capped at 15%. Previously, repayments exceeded twenty percent.
Broader Context
This agreement follows a protracted row between the drug companies and the British authorities over medicine costs and approval rates.
The disagreement were heightened by claims that US patients were paying several times more for the same drugs than patients in the UK and Europe.
In recent months, several large pharmaceutical investments in the UK have been halted or abandoned, while substantial investments have been pledged toward American operations.
A senior figure stated that the NHS must invest a greater share on medicines, noting that its expenditure on drugs had shrunk as a proportion of its resources over the past decade.
